Amoxicillin Sodium and Clavulanate Potassium for Injection

This product is a compound preparation of amoxicillin sodium and clavulanate potassium. Amoxicillin is a broad-spectrum penicillin antibiotic. Clavulanate potassium itself has only weak antibacterial activity, but has a strong broad-spectrum β-lactamase inhibitory effect. The combination of the two can protect amoxicillin from β-lactamase hydrolysis. The antibacterial spectrum of this product is the same as that of amoxicillin, and has been expanded. It has a good effect on enzyme-producing Staphylococcus aureus, Staphylococcus epidermidis, coagulase-negative Staphylococci and enterococci. It also has good antibacterial activity against some β-lactamase-producing Enterobacteriaceae, Haemophilus influenzae, Moraxella catarrhalis, Bacteroides fragilis, etc. This product has no effect on methicillin-resistant Staphylococcus aureus and Enterobacter, which produce chromosome-mediated enzymes, and Pseudomonas.

This product is a compound preparation, and its components are: each 0.6g contains 0.5g of amoxicillin sodium as amoxicillin and 0.1g of clavulanate potassium as clavulanic acid.

Strong Amoxicillin is suitable for respiratory tract infections caused by sensitive bacteria (pneumonia, acute and chronic bronchitis and secondary infections after colds, etc.), digestive tract infections (acute and chronic gastroenteritis, liver and bile tract infections, etc.), urinary tract infections (gonorrhea, non-gonococcal urethritis, pyelonephritis, cystitis, etc.), ear, nose, throat and skin soft tissue infections (otitis media, rhinitis and sinusitis, alveolitis, fossa tissue inflammation, etc.), diphtheria, whooping cough, typhoid fever, sepsis, endocarditis and leptospirosis, etc.

Intravenous injection or intravenous drip. Adults: 1.2g each time, 3-4 times a day. The course of treatment is 10-14 days. Children: 30mg/kg each time, 3-4 times a day (newborns: 2-3 times a day).

1. A small number of patients may experience gastrointestinal reactions such as nausea, vomiting, and diarrhea. After symptomatic treatment, the drug can be continued. 2. Urticaria and rash may occur occasionally (especially in patients with infectious mononucleosis). If they occur, the drug should be discontinued and symptomatic treatment should be given. 3. Anaphylactic shock, drug fever, and asthma may occur. 4. Elevated serum aminotransferase, eosinophilia, leukopenia, and superinfection caused by Candida or drug-resistant bacteria may occur occasionally. 5. Literature reports that some patients developed phlebitis at the injection site.

It is contraindicated for patients with positive penicillin skin test reaction, those who are allergic to this product and other penicillins, and those with infectious mononucleosis.

1. Aspirin, indomethacin, phenylbutazone, and sulfonamides can reduce the excretion of this product in the renal tubules, thereby increasing the blood concentration of this product, prolonging the blood elimination half-life (t1/2#61538;), and possibly increasing toxicity. 2. When this product is used in combination with allopurinol, the incidence of rash increases significantly, so it should be avoided. 3. This product should not be used in combination with aldehyde dehydrogenase inhibitors such as disulfiram. 4. When this product is used in combination with chloramphenicol for bacterial meningitis, the incidence of long-term sequelae is higher than when either is used alone. 5. This product can stimulate estrogen metabolism or reduce its enterohepatic circulation, thus reducing the effectiveness of oral contraceptives. 6. Antibiotics such as chloramphenicol, erythromycin, tetracyclines, and antibacterial drugs such as sulfonamides can interfere with the bactericidal activity of this product, so it is not suitable to be used in combination with this product, especially in the treatment of meningitis or severe infections that urgently require bactericidal drugs. 7. This product can enhance the effect of warfarin. 8. Aminoglycoside antibiotics at sub-inhibitory concentrations can generally enhance the in vitro bactericidal effect of this product against Enterococcus faecalis.

Sealed, stored in a dark, cool and dry place. (≤20℃)

0.6g

Hainan Meimei Xilin Biopharmaceutical Co., Ltd.

• Founded in:

  2007-12-24

• Address:

  Factory Building No. 26, Guilinyang Development Zone, Meilan District, Haikou City

• Tax NO.:

  91460000798744593P

• Registered Funds:

  10 million yuan

• Website:

  Log in to view

• Email:

  Log in to view